Lumos Pharma reports Q3 net loss $7.5M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 23 2024
0mins
Should l Buy ?
Operating Expenses and Financial Performance: For Q3 2024, the company reported operating expenses of $8.4 million and a net loss of $7.5 million.
Cash Position and Guidance Update: As of September 30, 2024, the company's cash balance was $13.5 million, and it has withdrawn its previous cash runway guidance without providing new guidance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
